MeiraGTx Holdings PLC
$ 10.03
-1.38%
22 Apr - close price
- Market Cap 941,307,000 USD
- Current Price $ 10.03
- High / Low $ 10.59 / 9.94
- Stock P/E N/A
- Book Value -0.07
- EPS -1.37
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -3.68 %
- 52 Week High 11.85
- 52 Week Low 4.55
About
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Analyst Target Price
$27.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-12 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-11 |
| Reported EPS | 0.19 | -0.62 | -0.48 | -0.51 | -0.5 | -0.55 | -0.76 | -0.32 | -0.42 | -0.74 | -0.53 | -0.62 |
| Estimated EPS | -0.564 | -0.5 | -0.4733 | -0.5 | -0.56 | -0.52 | -0.4 | -0.5 | -0.11 | -0.55 | -0.57 | -0.66 |
| Surprise | 0.754 | -0.12 | -0.0067 | -0.01 | 0.06 | -0.03 | -0.36 | 0.18 | -0.31 | -0.19 | 0.04 | 0.04 |
| Surprise Percentage | 133.6879% | -24% | -1.4156% | -2% | 10.7143% | -5.7692% | -90% | 36% | -281.8182% | -34.5455% | 7.0175% | 6.0606% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.62 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGTX
2026-04-22 13:44:25
Piper Sandler has increased its price target for MeiraGTx Holdings plc (MGTX) to $30 from $26, maintaining an Overweight rating, citing promising three-year data for its xerostomia treatment and the reacquisition of the bota-vec gene therapy. The company has also completed a $100 million equity raise to extend its cash runway. These developments have led to other analysts, including RBC Capital and H.C. Wainwright, also raising their price targets for MGTX.
2026-04-22 01:10:17
MeiraGTx Holdings plc's CFO & COO, Richard Giroux, sold 56,000 Ordinary Shares at a weighted average price of $10.22 per share, totaling $572,320. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the sale, Giroux directly holds 971,530 Ordinary Shares and indirectly holds an additional 90,152 shares through an LLC and his spouse.
2026-04-22 01:10:17
This SEC filing (Form 144) for MeiraGTx Holdings plc details a proposed sale of 56,000 ordinary shares acquired through incentive compensation stock grant on June 7, 2018. The shares, valued at $572,545, are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of April 21, 2026. The filing indicates a neutral impact and sentiment.
2026-04-22 01:10:17
Richard Giroux, CFO and COO of MeiraGTx Holdings plc, sold 56,000 ordinary shares for $572,320 on April 21, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred after a challenging week for the company's shares. Despite other recent positive news like a $100 million share offering and reacquiring a gene therapy, Mr. Giroux continues to hold a significant number of shares, both directly and indirectly.
2026-04-20 22:40:41
Latham & Watkins LLP represented MeiraGTx Holdings plc (Nasdaq: MGTX) in an underwritten offering of 11,111,111 ordinary shares at US$9 per share, totaling approximately US$100 million in gross proceeds. The offering closed on April 17, 2026, with all shares sold by MeiraGTx. A corporate team from Latham & Watkins, led by partners Keith Halverstam and Jennifer Yoon, advised on the transaction, with additional counsel on healthcare, FDA, and investment adviser regulatory matters.
2026-04-20 13:39:32
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for MeiraGTx Holdings (NASDAQ:MGTX), citing positive gene therapy progress. The firm highlighted strong 36-month AQUAx study data for AAV-hAQP1, the regaining of full control over the bota-vec asset, and a recent $100 million financing round that funds operations through late 2028. These developments, along with recent pricing of a share offering and positive data, support the optimistic outlook despite the company not yet being profitable.
